Anacalypsis Therapeutics secures pre-seed funding led by Metavallon VC's Brain Gain Fund to advance AT001, a stapled peptide for LRRK2-associated Parkinson's disease.
Round Type
Pre-Seed
GreeceBiotechnologyHealth CareTherapeuticsInvestors
Description
Greece-based Anacalypsis Therapeutics has raised a pre-seed financing round led by Metavallon VC through its Brain Gain Fund to advance AT001, a stapled peptide targeting the LRRK2–FADD protein-protein interaction for Parkinson's disease. The funding will support a key in vivo efficacy study of AT001 in preclinical models and establish proof of concept. Proceeds will also fund Anacalypsis' broader pipeline of therapeutic and biomarker programs. The company was founded around research showing that pathogenic LRRK2 can engage the death-adaptor protein FADD and activate neuronal cell-death signaling.
Quick answer
Anacalypsis Therapeutics raised an undisclosed amount in a Pre-Seed round, dated September 21, 2026. Investors: Metavallon VC. Anacalypsis Therapeutics is based in Greece.
- How much did Anacalypsis Therapeutics raise?
- Anacalypsis Therapeutics raised an undisclosed amount in a Pre-Seed round on September 21, 2026.
- Who invested in Anacalypsis Therapeutics?
- Metavallon VC is named as investors in this round.
- What does Anacalypsis Therapeutics do?
- Anacalypsis Therapeutics is a Greece-based biotech startup developing AT001, a stapled peptide targeting the LRRK2–FADD protein-protein interaction for treating Parkinson's disease.
- Where is Anacalypsis Therapeutics based and how big is it?
- Anacalypsis Therapeutics is based in Greece. Fundz records about 6 employees.
- Who are the decision-makers at Anacalypsis Therapeutics?
- Fundz holds 1 contact at Anacalypsis Therapeutics, including the CSO & Co-founder. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Anacalypsis Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Alethio raised $90M (Series A) on November 5, 2026.
- MyoPax raised an undisclosed amount (Pre-Seed) on November 4, 2026.
- Biograil raised $22M on November 4, 2026.
- Emvena Therapeutics raised an undisclosed amount (Seed) on November 4, 2026.
- Thryv Therapeutics raised $30M (Series B) on November 3, 2026.
- Setara Biosciences raised $90M (Series A) on October 30, 2026.
Who to call at Anacalypsis Therapeutics, and when
A new round usually means Anacalypsis Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Anacalypsis Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Anacalypsis Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Anacalypsis Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Anacalypsis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Anacalypsis Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.